Kane Biotech Inc KNBIF

Technical analysis

[francoisl13]

To see this story with a different angle, let's look at a the technical analysis -- I know, I know it is believed not to be very accurate for micro-cap companies but considering the fact that volume of trades have been picking up this year for KNE why not looking at it ---.
Short Term: Phase 1. Neutral to Negative. The price is below both the EMA 10 and 30. The RSI is below 50. The price range is not very wide so, a news release could change this very quickly considering that the price seems to be holding up well in the $0,12 area.
Mid Term: Phase 3. Neutral to slightly positive. The price sits on the EMA30 but the ema10 is still above the EMA30 so, this is temporary weakness / accumulation level area. The RSI is right at 50.
Long Term: Phase 2. Positive. The price is above the EMA 10. The EMA10 is above the EMA30 whiuch is positive. The volume have picked up well since February of this year. Looks very well long-term.
Voil! It is what it is. Please feel free to comment and add to the above.
GLTA!

[KevinOleary]

TA is a useless summary of yesterday's trading statistics which are useless counts of how many shares traded and how many times sellers and buyers made a trade etc. I have never used TA. People buy and sell for the wrong reasons, so why should I waste time wondering what they are/were thinking, when I can figure where kne is going fto end up at, from the info provided by the ceo?  The

[francoisl13]

I'm using TA for entry and exit points, it seems to work for me for that very specific purposes. I agree that doing our DD and following closely what a company does is more important especially when you deal with a micro-cap like KNE. Agree on your poibnts about Revyve and DispersinB...I said many times before that I like how this company is managed and how they go to market. The only negative

[KevinOleary]

Their timelines are controlled by the FDA. FDA does not understand biofilms, so they keep wasting time asking questions. No one can tell when the FDA will make decisions, and you can't just call them up with info or to ask the FDA for advice. Pre-submission communication with the FDA is only done by appointment and they are booked up for months. One company that I was invested in said during

[francoisl13]

I understand KevinOleary. FDA dealys are common but it's been happening with the almost every aspects of their business in the past -- for example, look at the acne trial with UofMiami...it's been postponed numerous time. For my part, I'd rather see them being more conservative on the timeline and make sure they set the expectations at the right level so that  the investment

[KevinOleary]

There is no way to be conservative and somewhat accurate when you're dealing with the FDA because you have zero idea how long they will dither. For example, the Revyve product approval has no labelling claims other than it is a hydrogel. They didn't claim it works well, or even that the hydrogel deals with biofilms etc. It is my understanding that there is nothing on the label except this

[francoisl13]

Yup, the DispersinB approval process will take years to go through. This is why expanding the Revyve line of product makes a lot of sense financially since it coul help cover up for some cost associated with this lengthy process -- assuming that the Dept. of Defense won't pay for the whole testing program.  Not even talking about the acne pot'l, hair products, eyecare products, etc...